Immunostimulant-integrated acrylate nanocomposite adjuvants potentiate foot-and-mouth disease vaccine efficacy Authors: Lu Bai, Mingguang Hu, Haijun Zhou, Xiaoqi Chen, Fen Zhang, Yantao Li, Hua Cheng, Mengmeng Zhou Published: 2026 ABSTRACT Foot-and-mouth disease (FMD) is a viral infectious disease of artiodactyls that threatens the global livestock economy and public health security. Vaccination is employed to prevent the occurrence of infectious diseases, and adjuvants play a key role in vaccine preparation. Commercially available FMD vaccines mainly use oil-emulsion adjuvants that induce a humoral immune response in the body. Based on the acrylate hydrogel adjuvant (AHN) with sustained-release properties, this study introduced CpG, Poly I:C, and QS-21 immunostimulants to create an prepare immunostimulant-integrated acrylate nanocomposite adjuvant (AHN@X) combining excellent antigen delivery capability and immune response direction regulation for use in FMD vaccines. AHN@X has a particle size of less than 100 nm, and it exhibits good storage stability at 4 °C. The FMD vaccines prepared with AHN@X nanocomposite adjuvant were immunized by intramuscular injection in BALB/c mice. The results showed that it could efficiently induce specific IgG, IgG1 and IgG2a antibody titers and activate B cells and T cells. Moreover, AHN@C stimulated splenocytes to secrete cytokines IFN-γ and IL-4 at the highest concentrations, 58.34 pg/mL and 32.24 pg/mL respectively. Additionally, the AHN@C nanocomposite adjuvant promoted the strongest endocytosis of antigens by macrophages, and it efficiently induced humoral immune responses and cellular immune responses. Overall, the clinical protective efficacy of AHN@C against FMDV is worth subsequent validation in target livestock animals. Introduction Foot-and-mouth disease (FMD) is an acute infectious disease caused by the foot-and-mouth disease virus (FMDV), which mainly infects pigs, cattle, sheep and other cloven-hoofed animals (Aslam and Alkheraije, 2023; Jamal and Belsham, 2013; Kim et al., 2024). Vaccination is the main core strategy for preventing and controlling FMD. Although inactivated FMDV, antigens have been widely used, they still face challenges such as insufficient immunogenicity, a short immune protection period, and potential biological safety risks (Kenubih, 2021; Niedbalski et al., 2019; Streicker et al., 2024). Moreover, traditional adjuvants or oil-emulsion adjuvants induce low antibody titers, cause local side effects, require periodic immunity boosting, and are weak in inducing cellular immunity, which also plays an indispensable role in clearing viruses and establishing lasting protection (Ma et al., 2023; Marrack et al., 2009; Tang et al., 2025). Similarly, traditional adjuvant types face marked side effects, high costs, and limitations in inducing excessive inflammatory responses, and they are increasingly inadequate in addressing the emergence of various infectious diseases (Tahara et al., 2022). As the immune evasion mechanisms of infectious pathogens such as FMDV are complex, humoral immunity alone cannot effectively prevent them (Yin et al., 2025). Thus, the development of new adjuvants that are both safe and efficient is one of the key means to improving the efficacy of FMD vaccines. Note that nanomaterials provide opportunities for the development of vaccine adjuvants. With their unique size effect, high specific surface area, and biocompatibility, nanomaterials can better defend antigens against the influence of biological enzymes, enhance the immunogenicity of antigens, and promote the delivery of antigens to antigen-presenting cells (APCs), thus effectively activating immune responses (Cai et al., 2024; Fries et al., 2021; Tehrani et al., 2023; Wang et al., 2023). Research has shown that nanoparticles with a particle size of 10–100 nm can be effectively absorbed through lymphatic drainage and effectively retained in lymph nodes (Foged et al., 2005; Kaminskas and Porter, 2011; McCright et al., 2022; Reddy et al., 2007). Among them, polymer nanomaterials possess good biocompatibility, and polymers such as chitosan, polyacrylate, and polylactic acid have been found to be promising candidate materials in the vaccine adjuvant field (Kabanov, 2004; Kumar et al., 2023; Liao et al., 2023; Sawaengsak et al., 2014; Sun et al., 2018). Moreover, synthetic polymer materials are often more controllable than natural polymers (Sadeghi et al., 2021; Terzopoulou et al., 2022). Polyacrylate is a cross-linked network polymer with good biocompatibility. This material can achieve the slow release of loaded antigens or drugs by establishing a three-dimensional network structure hydrogel, thus prolonging the immune stimulation time and markedly enhancing the body's humoral immune response. Based on polyacrylate nanoemulsion, further introducing functional components that can activate cellular immune responses can help induce stronger T-cell immune responses(Chandrudu et al., 2016; Krashias et al., 2010). Currently, ISA 201 and ISA 206 are commonly used commercial adjuvants for FMD vaccines. While they can induce strong humoral immune responses, their high mineral oil content often causes local adverse reactions such as injection site swelling and nodules. Moreover, mineral oil is difficult for the body to metabolize, thus posing safety risks. However, some polymer-based nanoparticle adjuvants, such as polylactic acid and chitosan, exhibit good biocompatibility, but their preparation processes are complex, their synthesis is costly, and large-scale production is challenging (Li et al., 2024; Lv et al., 2026; Zheng et al., 2020). In contrast, the AHN adjuvant developed in this study retains the biological safety advantages of polymer adjuvants while exhibiting good application potential through its low mineral oil content and simple preparation process, and it also reduces the risk of adverse reactions. Adjuvants guide and enhance specific immune responses by targeting innate immune cells and activating pattern recognition receptor (PRR) signaling pathways(Akira et al., 2006; Coffman et al., 2010; Kawai and Akira, 2010; Pulendran and Ahmed, 2006). Toll-like receptors (TLRs) hold marked application value in the vaccine adjuvant field. Notably, the signaling pathways mediated by TLRs are mainly divided into myeloid differentiation factor 88 (MyD88)-dependent and MyD88-independent pathways (Ciesielska et al., 2021; Nilsen et al., 2015). Cytosine-phosphate-guanine oligodeoxynucleotide (CpG) and polyinosinic-polycytidylic acid (Poly I:C) are mainly recognized by TLR9 and TLR3 on the endosomal membrane, respectively. Moreover, CpG activates nuclear factor kappa-B (NF-κB) through the MyD88-dependent signaling pathway, while Poly I:C mainly acts via the MyD88-independent pathway, thus activating the interferon regulatory factor (IRF) signaling pathway through TIR-domain-containing adapter-inducing interferon-β (TRIF) and phosphatidylinositol 3-kinase (PI3K), which, in turn, induces a Th1-type cellular immune response and stimulates the production of various cytokines, such as IFN-γ(Alexopoulou et al., 2001; Yamamoto et al., 2003). While the saponin extract QS-21 does not directly target specific PRRs, it can activate the NOD-like receptor family, the pyrin domain containing 3 (NLRP3) inflammasome, which is in the nucleotide oligomerization domain-like receptor (NLR) family of PRRs, and it indirectly initiates the MyD88-dependent signaling pathway, thus inducing Th1-type cytokines including IL-2 and IFN-γ(Detienne et al., 2016; Fernandez-Tejada et al., 2016; Marty-Roix et al., 2016; Zhu and Tuo, 2015). However, small-molecule immunostimulants have certain limitations when used alone, such as poor in vivo stability, susceptibility to enzymatic degradation, low transmembrane transport efficiency, and certain toxicity (Engel et al., 2011; Hemmi et al., 2000; Kensil and Kammer, 1998). Therefore, establishing composite adjuvants with multiple immunomodulatory effects based on synthetic polymers with sustained-release properties is a core strategy for developing novel adjuvants. In this study, immunostimulants of CpG, Poly I:C, or QS-21 with immunomodulatory effects and acrylate hydrogel adjuvants with sustained-release effects were established to construct acrylate nanocomposite adjuvants with both excellent antigen delivery capabilities and immune response-guided regulation functions. Using the inactivated type O FMDV as the antigen, we prepared a vaccine, and its physicochemical properties, safety, and enhancement effects on FMDV-specific humoral and cellular immune responses were systematically investigated. We also undertook an exploration of its action mechanism. By comparing the adjuvant effects of three immune stimulants in this nanodelivery platform, we aimed to screen out the most suitable compound adjuvant for the inactivated FMD vaccine, which holds important application value. Experiment Materials Poly I:C was purchased from Kaipeng Bio-Technology Co., Ltd. CpG was purchased from PARR Bio-Technology Co. Ltd. Goat anti-Mouse IgG/HRP was purchased from Beijing Noble Ryder Technology Co., Ltd., and Goat anti-Mouse IgG1 and Goat anti-Mouse IgG2a were purchased from Thermo Fisher Scientific Co., Ltd. IL-4 and IFN-γ cytokine detection kit was purchased from Shanghai Enzyme Biotechnology Co., Ltd. Fetal bovine serum was purchased from Lanzhou Roya Bio-Technology Co., Ltd. QS-21 and FMDV type O antigen were supplied by Jinyu Bio-Technology Co. Ltd. Acrylate hydrogel adjuvant (containing acrylate hydrogel and nanoemulsion, AHN) was homemade by the research group. Preparation of immunostimulant-integrated acrylate nanocomposite adjuvants Using acrylic acid as the main reactive monomer, 21 g of acrylic acid, 0.315 g of dodecyl acrylate, 0.294 g of pentaerythritol triallyl ether, 0.105 g of azobisisobutyronitrile, 0.126 g of Span 60, and 0.21 g of NaHCO3 were added to a solvent system consisting of ethyl acetate and cyclohexane. The mixture was mechanically stirred at 75 °C under a nitrogen atmosphere for 4 h, and the polyacrylate was obtained by suction filtration. The polyacrylate was fully swollen in pure water, and the pH was then adjusted to neutrality to form a 1 wt% acrylate hydrogel. The acrylate hydrogel was subsequently mixed with oil-in-water nanoemulsion at a 2:1 ratio to obtain an AHN adjuvant containing 2.25% mineral oil. AHN adjuvants were compounded with 10 mg/mL of CpG, Poly I:C or QS-21 immunostimulant to prepare immunostimulant-integrated acrylate nanocomposite adjuvant (AHN@X), where X = C, P, and Q represent CpG, Poly I:C, and QS-21, respectively. The structural formulas of acrylate and immunostimulants are shown in Table S1. Preparation and immunization of FMD vaccine The AHN and 40 μg/mL FMDV antigen were mixed by vortex at 1000 rpm for 2 min to prepare FMD vaccines. Then, BALB/c mice (16–18 g, female) were chosen as the animal model. The mice were randomly divided into five groups (n = 6), and the FMD vaccine was injected into the thigh muscle of each mouse at a volume of 100 μL per mouse. The FMDV pure antigen group was prepared by using 5 mL of FMDV and 5 mL of PBS, while the adjuvant group was prepared by using 3 mL of AHN/AHN@X adjuvant, 10 mL of FMDV, and 7 mL of PBS. Subsequently, the vaccines were sterilized by 0.22 μm sterile filter. The antigen dose per mouse was 2 μg, and the immunostimulant dose was 30 μg. The FMD vaccine formulation is listed in Table 1.Table 1Foot-and-mouth disease vaccine formulation and dose per mouse.GroupFormulationImmunostimulant/μgFMDV/μgFMDV5 mL “O” FMDV, 5 mL PBS–2AHN3 mL AHN, 10 mL “O” FMDV, 7 mL PBS–2AHN@C3 mL AHN@C, 10 mL “O” FMDV, 7 mL PBS302AHN@P3 mL AHN@P, 10 mL “O” FMDV, 7 mL PBS302AHN@Q3 mL AHN@Q, 10 mL “O” FMDV, 7 mL PBS302 Table 1Foot-and-mouth disease vaccine formulation and dose per mouse.GroupFormulationImmunostimulant/μgFMDV/μgFMDV5 mL “O” FMDV, 5 mL PBS–2AHN3 mL AHN, 10 mL “O” FMDV, 7 mL PBS–2AHN@C3 mL AHN@C, 10 mL “O” FMDV, 7 mL PBS302AHN@P3 mL AHN@P, 10 mL “O” FMDV, 7 mL PBS302AHN@Q3 mL AHN@Q, 10 mL “O” FMDV, 7 mL PBS302 Foot-and-mouth disease vaccine formulation and dose per mouse. Mice were immunized two times in total, with the second immunization being administered 14 days after the first. Moreover, blood samples were collected from the medial canthus of the mouse 14 and 28 days after the first vaccination. Following blood collection, the samples were placed at 37 °C for 1 h and then kept at 4 °C overnight and centrifugated at 1000 rpm for 10 min. The upper serum was aspirated, while the serum was frozen and stored in the refrigerator for later use. All animal experiments were approved by the Biomedical Ethics Committee of Shijiazhuang University (Approval number: LACUC-SJZU-2025-04008). Furthermore, randomization and blinding were applied during animal experiments and data analysis. Characterization Physical and chemical properties The micromorphology of the adjuvant was observed using a transmission electron microscope (TEM, JEM-2100 Plus, Japan Electronics). The particle size and zeta potential of the adjuvants were characterized using a dynamic light scattering particle size analyzer (PSS Z3000, USA), and monitored the changes in mean particle diameter on days 1, 5, 10, 20, 30, 40, and 50 after storage at 4 °C and 37 °C respectively. Safety Cytotoxicity assay Macrophages were isolated according to the method described in the supplemental materials, adjusted to a concentration of 1 × 106 cells/mL, and spread into cell culture plate. After culturing and adhesion, the medium was discarded, and an RPMI-1640 complete medium containing 10% fetal bovine serum (FBS) was added to each well. Subsequently, filter-sterilized AHN@X was added to the cell culture plate, with the concentrations of the immunostimulants being 10, 5, 1, and 0 μg/mL, with five replicate wells for each concentration. Then, cell control wells and blank wells were set up. After incubation for 24 h, the CCK-8 assay was performed, and the absorbance at 450 nm was measured using Multiskan GO (Thermo Scientific, USA). Cell viability was computed to evaluate the cytotoxicity of the drug, as follows:Cell viability=As−AbAc−Ab×100%where As is the absorbance of the experimental well (cells, culture medium, CCK-8, drugs), Ac denotes the control well (cells, culture medium, CCK-8), and Ab signifies the blank well (culture medium, CCK-8). Weight monitoring During the immune test of the FMD vaccine, the weight of BALB/c mice in all groups was observed on days 1, 2, 3, 5, 8, 11, 14, 17, 20, 24, and 28 (n = 6) to evaluate whether the vaccine prepared by the acrylate hydrogel nanocomposite adjuvant and FMDV antigen would cause side effects like as weight loss after intramuscular injection into the mice. Evaluation of immune response The ELISA antigen-antibody specific binding method was employed to detect IgG, IgG1, and IgG2a antibodies in the serum of BALB/c mice (n = 6) following immunization. The inactivated FMDV antigen was diluted to 1 μg/mL with coating buffer, added to a 96-well ELISA plate at 200 μL per well, and incubated overnight at 4 °C. The plates were then washed three times, 200 μL of blocking buffer (newborn calf serum: washing buffer = 1:9) was added to each well, and then the plate was blocked at 37 °C for 1 h. The plates were washed, and then diluted immune mouse serum samples were added and incubated at 37 °C for 2 h. The plates were rewashed, and then 100 μL of diluted goat anti-mouse IgG/HRP, IgG1/HRP, or IgG2a/HRP was added to each well and incubated at 37 °C for 1 h. After another wash, 100 μL of substrate solution was added to each well, and the plate was incubated at 37 °C for 15 min. The reaction was halted by adding stop solution, and the OD450nm value was immediately measured using a Multiskan Go instrument. Evaluation of cytokine secretion levels Mice were randomly chosen from each group for cytokine secretion testing (n = 3). Spleen cells isolated from immunized mice were adjusted to a concentration of 1 × 106 cell/mL and then spread into cell culture plates. Each well was stimulated and cultured with FMDV at a concentration of 5 μg/mL for 24 h. The splenocytes stimulated and cultured by FMDV antigen were centrifuged at 1000 rpm for 10 min, and the cell supernatants were collected and utilized to detect IL-4 and IFN-γ cytokines using ELISA kits. Flow cytometry Next, mice were randomly selected from each group for cell flow cytometry testing (n = 3). Spleen cells isolated from immunized mice were adjusted to a concentration of 4 × 106 cells/mL and then spread into cell culture plates. Each well was stimulated and cultured with FMDV at a concentration of 5 μg/mL for 24 h. Flow cytometry antibody labeling (anti-CD3, anti-CD4, anti-CD19, anti-CD69, anti-CD44, and anti-CD62L) was done on splenocytes to detect the activation of B cells and T cells, while flow cytometry (AFC2, Thermo Scientific, USA) was employed to detect splenocytes. Endocytosis of macrophages Macrophages were isolated according to the method described in the supplemental materials, adjusted to a concentration of 5 × 105 cells/mL, and spread into polylysine-coated cell culture plate. After culturing and adhesion, the medium was discarded, and RPMI-1640 complete medium containing 10% FBS was added to each well. AHN and AHN@X were then combined with FITC-OVA and added to the cell culture plates. At the same time, the blank control group and FITC-OVA control group were established. After 24 h of culture, the medium was discarded, and the plates were washed twice with PBS, fixed with 4% paraformaldehyde for 20 min, washed three times with PBS, stained with DAPI in the dark for 5 min, washed three times with PBS, and then the anti-fluorescence attenuation mounting agent was added. The macrophage phagocytic ability was observed using an inverted fluorescence microscope (Axio observer, ZEISS, Germany). The concentration of AHN and AHN@X in each well was 1 mg/mL, the concentration of immunostimulant in each well was 5 μg/mL, and the concentration of FITC-OVA was 25 μg/mL. All samples were sterilized by filtration. Statistical analysis Statistical analysis was conducted using GraphPad Prism 8.0 software for ANOVA, along with Tukey's honestly marked difference test. Data are presented as the mean ± standard error (mean ± SD). P < 0.05 was considered as a marked difference. The sample size is shown in the legend or the description in the main text. Results and discussion Physical and chemical properties The immunostimulants CpG, QS-21, and Poly I:C were respectively combined with AHN to prepare acrylate nanocomposite adjuvants, and their appearance, particle size, zeta potential, stability, and micromorphology were characterized (Fig. 1 and Table S2). As shown in Fig. 1a, AHN, AHN@C, AHN@P and AHN@Q were diluted with PBS buffer at 15 wt%. All the samples showed blue light transmission. Fig. 1b illustrates the particle size and polydispersity index (P.I.). The results show that the mean particle diameter of AHN, AHN@C, AHN@Q and AHN@P was 45.83, 46.20, 46.67, and 45.57 nm, respectively, and that the P.I. was 0.220, 0.445, 0.109, and 0.141, respectively. This result shows that the particle size of the nanocomposite adjuvants was less than 100 nm and achieved good dispersion. The introduction of immunostimulants has little effect on the particle size and P.I.. As shown in Fig. 1 (c-d), the initial particle size of AHN and AHN@X adjuvant samples were less than 100 nm at storage temperatures of 4 °C and 37 °C. With an extended storage time, the mean particle diameter of AHN and AHN@X adjuvant samples changed little at 4 °C, while at the body temperature of 37 °C, the increase in particle size for both adjuvants was approximately 22–24 nm. In contrast, the storage environment of 4 °C was more conducive to maintaining the long-term storage stability of nanocomposite adjuvants. Table S3 shows that the AHN@X composite adjuvant samples maintained a non-stratified state at 4 °C and 37 °C. Additionally, the prepared FMD vaccine also had good storage stability, and the results are shown in Fig. S1. As shown in Fig. 1e, the zeta potentials of AHN, AHN@C, AHN@Q and AHN@P were −36.34, −41.43, −38.12, and −40.25 mV, respectively. A high absolute value of zeta potential indicates a stable dispersion system, where strong mutual repulsion between particles makes it difficult for them to aggregate, and the suspension is not vulnerable to sedimentation, flocculation, or coagulation. Moreover, the nanocomposite adjuvants in the system present stable and uniform particles. TEM was empolyed to characterize and analyze the microstructure morphology, and the results are shown in Fig. 1f, where the nanoparticle sizes were all less than 100 nm. Studies have shown that nanoparticles in the range of 10–100 nm are optimal for adjuvants, as this range is conducive to efficient lymph node targeting of adjuvants and maximizes synergistic activation effects (Foged et al., 2005; Kaminskas and Porter, 2011; McCright et al., 2022; Reddy et al., 2007).Fig. 1Physicochemical properties of the AHN and AHN@X adjuvants: (a) Appearance; (b) Mean particle diameter and P.I.; (c-d) Storage stability at ambient temperatures of 4 °C and 37 °C; (e) Particle size distribution and zeta potential; (f) Micromorphology.Fig. 1 Physicochemical properties of the AHN and AHN@X adjuvants: (a) Appearance; (b) Mean particle diameter and P.I.; (c-d) Storage stability at ambient temperatures of 4 °C and 37 °C; (e) Particle size distribution and zeta potential; (f) Micromorphology. Safety The cytotoxicity of acrylate nanocomposite adjuvants with different doses of immunostimulants was observed, and the cell viability was calculated according to the formula in Section 2.4.2.1, with the results being shown in Fig. 2a. As shown in the figure, as the concentration of immunostimulants gradually decreased, cell viability exhibited an increasing trend, revealing that high drug concentrations had a marked inhibitory effect on cells. Under the same immunostimulant concentration, the cell viability followed the order AHN@C > AHN@P > AHN@Q. This could be because QS-21 exerts direct physicochemical toxicity that damages the cell membrane, leading to apoptosis, whereas Poly I:C and CpG exhibit biological immune toxicity that requires the activation of signaling pathways in the body to indirectly induce apoptosis. Further, when the immunostimulant concentration was 10 μg/mL, the cell viability of AHN@X composite adjuvant reached 70% to 80%. When the immunostimulant concentration was 5 or 1 μg/mL, the cell viability did not much differ considerably. The cell viability of AHN@C and AHN@P exceeded 80%. The AHN@C composite adjuvant introducing CpG had the lowest cytotoxicity and better biosafety, being 77.27%, 83.65%, and 86.05% at 10, 5, and 1 μg/mL, respectively.Fig. 2Safety of adjuvant: (a) Cytotoxicity of macrophages treated with AHN and AHN@X for 24 h, as assessed by CCK8 assay (n = 5, data were analyzed using two-way ANOVA); (b) Weight monitoring of FMDV, AHN and AHN@X with time of initial immunization (n = 6). Data are presented as the mean ± SD. ⁎P < 0.05, ⁎⁎P < 0.01.Fig. 2 Safety of adjuvant: (a) Cytotoxicity of macrophages treated with AHN and AHN@X for 24 h, as assessed by CCK8 assay (n = 5, data were analyzed using two-way ANOVA); (b) Weight monitoring of FMDV, AHN and AHN@X with time of initial immunization (n = 6). Data are presented as the mean ± SD. ⁎P < 0.05, ⁎⁎P < 0.01. AHN, AHN@C, AHN@P, and AHN@Q adjuvants were each mixed with the inactivated FMDV antigen to create the vaccines. The vaccines were delivered via intramuscular injection for immunization, and the weight changes of mice were observed to assess the effect of the acrylate nanocomposite adjuvants. As shown in Fig. 2b, the weight of mice in each group showed an increasing trend with time. The use of the nanocomposite adjuvants did not exert adverse effects such as the loss of appetite or weight suppression, revealing that the nanocomposite adjuvants did not generate obvious toxic side effects in the mice. Analysis of antibody levels in serum immune to FMD vaccine To evaluate the level of immune response induced by the acrylate nanocomposite adjuvants in FMD vaccine, we measured the IgG, IgG1, and IgG2a antibody titers in the serum of BALB/c mice at 14 and 28 days after the initial immunization, and the results are shown in Fig. 3. As shown in Fig. 3a, the IgG antibody titers of the AHN and AHN@X adjuvant groups exceeded those of the FMDV antigen group, and the nanocomposite adjuvant containing CpG immunostimulant induced the highest level. Moreover, IgG1 and IgG2a are IgG antibody subtypes, and their antibody titers are shown in Fig. 3 (b, c). The IgG1 and IgG2a antibody titers produced by AHN@C nanocomposite adjuvant were the highest on days 14 and 28 of the initial immunization. The ratio of IgG2a/IgG1 might reflect immune tendency. As shown in Fig. 3d, on the day 14 of the initial immunization, IgG2a/IgG1 > 1, AHN and AHN@X adjuvant groups were both higher than those of the FMDV group. The adjuvant groups all exhibited an immune response in which the Th1-type cellular immune response was dominant, while the Th2-type humoral immune response was auxiliary. Then, on day 28 after initial immunization, the IgG2a/IgG1 ratio was <1 for the FMDV, AHN, and AHN@Q groups, while it was greater than 1 for the AHN@C and AHN@P groups, indicating that at 28 days of initial immunization, the AHN@C and AHN@P composite adjuvants tended to continuously induce a much stronger Th1-type cellular immune response, while AHN and AHN@Q tended to induce a predominantly Th2-type humoral immune response. In conclusion, AHN@X nanocomposite adjuvant could induce cellular and humoral immune responses at the same time, and it was more prone to cellular immunity in the early immunity stage. In the late immunity stage, moreover, AHN@C and AHN@P still maintained a strong Th1-type cellular immune response tendency, but AHN@Q was more inclined to Th2-type humoral immune response. Additionally, for the other mice (n = 3) that did not undergo the flow cytometry and other tests, the antigen-specific IgG titer at 56 days after the initial immunization was assessed. The results are shown in Fig. S2. It was found that the titer stayed at the same level as that at 28 days after the initial immunization in both the AHN@C and AHN@P composite adjuvant groups and that the titer in the latter group was slightly higher, indicating that AHN@X has the characteristic of sustained antigen release.Fig. 3Specific antibody response of FMDV, AHN and AHN@X measured by ELISA on days 14 and 28 post-immunization: (a) IgG antibody titer; (b) IgG1 antibody titer; (c) IgG2a antibody titer; (d) IgG2a/IgG1 ratio. Data were analyzed using two-way ANOVA and presented as mean ± SD. N = 6, ⁎P < 0.05, ⁎⁎P < 0.01.Fig. 3 Specific antibody response of FMDV, AHN and AHN@X measured by ELISA on days 14 and 28 post-immunization: (a) IgG antibody titer; (b) IgG1 antibody titer; (c) IgG2a antibody titer; (d) IgG2a/IgG1 ratio. Data were analyzed using two-way ANOVA and presented as mean ± SD. N = 6, ⁎P < 0.05, ⁎⁎P < 0.01. Cytokine secretion The secretion levels of IL-4 and IFN-γ are related to immune response. Specifically, IL-4 induces T cells to differentiate into Th2 subpopulation, which is related to humoral immunity. IFN-γ induces T cells to differentiate into Th1 subgroup, which is associated with cellular immunity. Therefore, the Th1/Th2 immune response tendency was further evaluated by characterizing and analyzing the levels of IL-4 and IFN-γ cytokines secreted in mice splenocyte culture fluid 28 days after immunization, and the results are shown in Fig. 4.Fig. 4Cytokine secretion levels of spleen cells stimulated by FMDV (5 μg/mL) for 24 h on day 28 post-immunization: (a) IL-4; (b) IFN-γ; (c) IFN-γ/IL-4 ratio. Data were analyzed using one-way ANOVA and presented as mean ± SD. n = 3, ⁎P < 0.05, ⁎⁎P < 0.01.Fig. 4 Cytokine secretion levels of spleen cells stimulated by FMDV (5 μg/mL) for 24 h on day 28 post-immunization: (a) IL-4; (b) IFN-γ; (c) IFN-γ/IL-4 ratio. Data were analyzed using one-way ANOVA and presented as mean ± SD. n = 3, ⁎P < 0.05, ⁎⁎P < 0.01. The IL-4 and IFN-γ cytokines induced by stimulating splenocytes in immunized mice were calculated based on the standard curves y = 99.31×-5.65 and y = 343.36×-16.94, as shown in Fig. S3. As shown in Fig. 4(a,b), the concentration of IL-4 secreted by splenocytes induced by FMDV, AHN, AHN@C, AHN@P, and AHN@Q was 20.03, 24.59, 32.24, 29.29, and 27.54 pg/mL, respectively. Moreover, the concentration of IFN-γ secreted by splenocytes induced by FMDV, AHN, AHN@C, AHN@P, and AHN@Q was 16.15, 24.14, 58.34, 40.55, and 26.05 pg/mL, respectively. The AHN@X nanocomposite adjuvant group of immune stimulants could enhance the expression levels of IL-4 and IFN-γ cytokines in spleen cells, and it showed marked differences compared with the FMDV pure antigen group and the AHN group. Among them, the cytokine secretion level of AHN@C showed marked differences compared with AHN@Q and AHN@P. The IFN-γ/IL-4 ratio was among the indicators of Th1/Th2 immune response tendency. The results in Fig. 4c show that the IFN-γ/IL-4 ratios of AHN@C, AHN@P and AHN@Q were 1.81, 0.95 and 1.52, respectively, and that there was a marked difference between AHN@C, AHN@P, and AHN@Q. The above results show that the introduction of CpG and Poly I:C immunostimulants could markedly enhance the cellular immune response. Activation of B cells and T cells The spleen is a secondary lymphoid organ that containing a variety of immune cells. The spleen of immunized animals is rich in memory lymphocytes, and re-stimulation with the same antigen can cause the proliferation and differentiation of memory lymphocytes. Flow cytometry was employed to measure the activation levels of B cells and T cells in the spleen cells of mice in each group after 28 days of immunization and the results are shown in Fig. 5.Fig. 5Percentages of B cells and T cells in spleen cells stimulated by FMDV (5 μg/mL) for 24 h were analyzed by flow cytometry on day 28 post-immunization: Activation and representative flow cytometry of lymphocytes in each group of mice on day 28 post-immunization: (a) B cell activation; (b) CD4+ T cell activation; (c) Central memory CD4+ T cells; (d) Effector memory CD4+ T cells; (e) Representative flow cytometry. Data were analyzed using one-way ANOVA and presented as mean ± SD. n = 3, ⁎P < 0.05, ⁎⁎P < 0.01.Fig. 5 Percentages of B cells and T cells in spleen cells stimulated by FMDV (5 μg/mL) for 24 h were analyzed by flow cytometry on day 28 post-immunization: Activation and representative flow cytometry of lymphocytes in each group of mice on day 28 post-immunization: (a) B cell activation; (b) CD4+ T cell activation; (c) Central memory CD4+ T cells; (d) Effector memory CD4+ T cells; (e) Representative flow cytometry. Data were analyzed using one-way ANOVA and presented as mean ± SD. n = 3, ⁎P < 0.05, ⁎⁎P < 0.01. CD69, which is expressed on the surface of activated B cells, T cells, and macrophages, functions largely as an activation-induced molecule and is an important activation marker for both B cells and T cells(Lindsey et al., 2007; Marzio et al., 1999). As shown in Fig. 5 (a, b), the levels of B cells and T cells secreted by spleen cells of mice in the AHN and AHN@X adjuvant immunization groups were higher, indicating that the nanocomposite adjuvant can better induce the activation of mouse lymphocytes. Likewise, memory T cells play an important role in controlling secondary infections and clearing pathogens. Central memory cells observe the lymphatic system through circulation, forming lifelong immune memory (Kaech et al., 2002). Effector memory T cells circulate in peripheral non-lymphoid tissues and can take effect immediately when exposed to antigens again to quickly induce immune responses. CD44 and CD62L are cell surface markers of memory cells. Among them, central memory T cells highly express CD44 and CD62L (CD44hiCD62Lhi) on their surfaces, and effector memory T cells express high CD44 levels and low 62 L levels (CD44hiCD62Llow). Fig. 5 (c, d) shows that the proportion of central memory and effector memory CD4+ T cells in the AHN, AHN@C and AHN@P adjuvant groups was higher than that in the FMDV group, which can better induce the formation of memory T cells. However, we observed no marked difference between the groups. A representative flow cytometry plot of this set of experiments is shown in Fig. 5e. In summary, BALB/c mice were immunized via intramuscular injection with inactivated FMDV as the antigen. Combining the levels of cytokines and cell activation, we observed that compared with the AHN group, the AHN@X nanocomposite adjuvant helps helped improve the body's humoral and cellular immune response to the FMDV inactivated virus, produced higher levels of IgG-specific antibodies, and stimulated the production of B cells and T cells at higher levels. Endocytosis of macrophages Different immunostimulants stimulate macrophage phagocytosis in differently. Notably, CpG and Poly I:C are recognized by Toll-like receptors 3 and 9 (TLR3 and TLR9) on macrophages, respectively, inducing the production of large amounts of type I interferon, thus activating macrophages and promoting the endocytosis and antigen presentation capabilities of macrophages (Krieg, 2002; Seya, 2008). The amphiphilic structure of QS-21 can directly combine with cholesterol on the cell membrane of macrophages to establish holes, which can enhance the permeability of the cell membrane, help antigens escape to the cytoplasm, and non-specifically activate the phagocytosis of macrophages (Marty-Roix et al., 2016). After macrophages were stained with DAPI, the cell nuclei exhibited blue fluorescence under an inverted fluorescence microscope. FITC-OVA mixed with the adjuvant was endocytosed by macrophages and then exhibited green fluorescence under an inverted fluorescence microscope. The results of the ability of macrophages to take up FITC-OVA antigen in different adjuvant groups are presented in Fig. 6.Fig. 6Endocytosis capacity of macrophages treated with FITC-OVA, AHN/FITC-OVA, and AHN@X/FITC-OVA for 24 h, as measured by an inverted fluorescence microscope. Green: FITC-OVA, blue: nuclei stained with DAPI. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)Fig. 6 Endocytosis capacity of macrophages treated with FITC-OVA, AHN/FITC-OVA, and AHN@X/FITC-OVA for 24 h, as measured by an inverted fluorescence microscope. Green: FITC-OVA, blue: nuclei stained with DAPI. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) As shown in Fig. 6, the FITC-OVA group only exhibited sporadic weak green fluorescence, and the green fluorescence intensity and area of the AHN group were increased compared with the FITC-OVA group, revealing that the AHN group had a certain ability to phagocytose antigens. Compared with the AHN group, the green fluorescence area of the AHN@X group increased s markedly, revealing the introduction of CpG, Poly I:C and QS-21 markedly enhanced the endocytosis of antigens by macrophages. Based on the intensity and surface of green fluorescence, at the same added dose of immunostimulants, the phagocytic ability of the AHN@X group was followed the order AHN@C > AHN@P > AHN@Q. Therefore, the nanocomposite adjuvant in this study could enhance the phagocytosis ability of macrophages against antigens, in particular, the introduction of CpG markedly enhanced the endocytosis of the composite adjuvant. Discussion The use of polymer nanoparticles to construct vaccine delivery platforms has emerged as a highly effective strategy for improving immune responses (Shi et al., 2025; Zhang et al., 2023). In this study, AHN@X nanoparticle composite adjuvants were constructed by integrating TLR agonists and saponin extracts into AHN (composed of acrylate hydrogel and oil-in-water nanoemulsion). The immune effect of AHN@X/FMDV vaccine in a BALB/c mouse model was evaluated. It is well established that nanoparticles with a size of 10–100 nm are more readily transported to lymphoid tissues via the lymphatic drainage system after injection, whereas larger particles rely on dendritic cell migration to the lymph nodes (Foged et al., 2005; Kaminskas and Porter, 2011; McCright et al., 2022; Reddy et al., 2007). The AHN@X composite adjuvant exhibited a particle size of less than 100 nm, with no significant change in size after antigen loading (Fig. 1 and Fig. S1), suggesting that this size range facilitates efficient lymphatic trafficking of the vaccine. Upon reaching the lymph nodes, the antigens were taken up and processed by immune cells (Fig. 6). Theoretically, after being processed, the antigens could be presented via MHC-II molecules for specific recognition by T-cell receptor (TCR), thereby triggering CD4+ T cell-mediated cellular immune responses. Meanwhile, the sustained-release properties of the acrylate hydrogel matrix in AHN@X could protect the FMDV antigen from rapid degradation, thereby enabling persistent antigen stimulation and sustained immune activation. These findings indicate that AHN@X synergistically promoted antigen uptake and immune activation through optimized physical dimensions and controlled release kinetics. Biosafety is a critical parameter for adjuvant evaluation. Consistent with previous reports, acrylate polymer adjuvants possess favorable biocompatibility and have been well documented as antigen carriers (Garinot et al., 2020; Pichon et al., 2026; Skwarczynski et al., 2010). Accordingly, we further assessed the cytotoxicity of AHN@X and found that the cell viability of AHN@C and AHN@P was superior to that of AHN@Q (Fig. 2a). To evaluate the ability of the AHN@X composite adjuvants to elicit antigen-specific immune responses, we measured serum antibody levels in mice and tracked them up to 56 days after the initial immunization. As shown in Fig. 3a, the incorporation of immunostimulants elicited more robust antigen-specific IgG antibody responses. This finding is consistent with previous reports on nanoparticle-based delivery systems, which demonstrated significantly enhanced antibody titers upon inclusion of immunostimulants (Bian et al., 2026; Kim et al., 2018). On day 28 post-immunization, AHN@C induced potent IgG1 and IgG2a levels and sustained a Th1-type cellular immune response, accompanied by elevated secretion of IFN-γ and IL-4 cytokines (Fig. 3b-d and Fig. 4). Furthermore, flow cytometry results revealed that, AHN@C concurrently activated both B cells and T cells compared to free FMDV antigen (Fig. 5). In contrast to commercially available FMD vaccines that predominantly elicit strong humoral immunity, the immunostimulant-integrated acrylate hydrogel composite adjuvant in this study elicited both robust humoral and cellular immune responses. We fully recognize that BALB/c mice are not the natural host for FMDV, and immune responses in mice may not fully predict vaccine efficacy in cloven-hoofed target animals. Nevertheless, in non-inferiority testing, the use of BALB/c mice as a surrogate model for swine in FMD vaccine studies could be justified to evaluate vaccine protective efficacy (Dong et al., 2015; Jiao and Wu, 2024). Additionally, the influence of adjuvants on the presence and integrity of antigens are also the points for future research. Although no challenge protection experiment was conducted in the present study, further studies are warranted to more comprehensively evaluate the adjuvant activity of AHN@X. Nonetheless, the results highlight the potent adjuvant potential of AHN@X in FMD vaccine preparation and provide a valuable reference for subsequent protective efficacy studies and dose optimization in target animals. Conclusion In this study, the AHN@X nanocomposite adjuvants were successfully constructed by integrating immunostimulants with the acrylate hydrogel adjuvant possessing sustained-release properties. The mean particle diameter of the nanocomposite adjuvant was less than 100 nm, and excellent stability at 4 °C. The acrylate nanocomposite adjuvant was combined with the type O FMDV antigen to prepare the FMD vaccine. After immunization, the AHN@X adjuvant efficiently induced the production of IgG, IgG1, and IgG2a antibody titers in mice, markedly enhanced the levels of IFN-γ and IL-4 secreted by splenocytes, and also efficiently induced the activation of B cells and T cells in the splenocytes of immunized mice. AHN@C nanocomposite adjuvant promoted the strongest macrophage endocytosis of antigens. In summary, the research on AHN@X nanocomposite adjuvants, especially AHN@C, provides a promising candidate for veterinary vaccine adjuvants and is well worth further evaluation in the target livestock animals. CRediT authorship contribution statement Lu Bai: Writing – review & editing, Writing – original draft, Validation, Methodology, Investigation, Formal analysis, Conceptualization. Mingguang Hu: Validation, Investigation, Formal analysis. Haijun Zhou: Validation, Resources, Formal analysis. Xiaoqi Chen: Validation, Resources, Formal analysis. Fen Zhang: Validation, Supervision. Yantao Li: Resources, Project administration, Methodology, Conceptualization. Hua Cheng: Validation, Resources. Mengmeng Zhou: Writing – review & editing, Supervision, Project administration, Methodology. Ethics declaration This study was conducted in accordance with the ARRIVE (Animal Research: Reporting of In Vivo Experiments) guidelines. This study was approved by the Biomedical Ethics Committee of Shijiazhuang University. Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.